It has been reported that retinoids may affect hypothalamic-pituitary- thyroid axis, causing central hypothyroidism. In the present study, we evaluated pituitary function in 11 male psoriatic patients at baseline and after 1 and 3 months of treatment with acitretin (all-trans retinoic acid, 35 mg/day). Serum LH, FSH, testosterone, cortisol, GH and IGF-I levels were not affected by the treatment. By contrast, we observed a significant decrease in TSH levels (from 0.92±0.3 to 0.80±0.3 mU/l, p<0.05) at 1 month, that reverted to baseline after 3 months. No change in free T4 (FT4) levels occurred, while free T3 (FT3) levels were reduced at 1 and 3 months (from 6.7±0.5 to 6.2±0.3 and 6.1±0.6 pmol/l; p<0.05, respectively). Moreover, acitretin treatment induced a significant reduction of PRL levels after 3 months (from 182±70 to 150±56 mU/l, p<0.05). During treatment, no change in TSH and PRL response either to TRH or dopamine infusion was observed. In conclusion, we demonstrated that treatment with low dose of acitretin induced a series of hormonal modifications that, in addition to a mild and transient reduction of TSH levels, included a persistent reduction of FT3, probably due to changes in thyroid hormone metabolism, and a decrease in PRL levels.
Effects of chronic retinoid administration on pituitary function / A.R. Angioni, A. Lania, A. Cattaneo, P. Beck-Peccoz, A. Spada. - In: JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION. - ISSN 0391-4097. - 28:11(2005), pp. 961-964.
Effects of chronic retinoid administration on pituitary function
A. LaniaSecondo
;P. Beck-PeccozPenultimo
;A. SpadaUltimo
2005
Abstract
It has been reported that retinoids may affect hypothalamic-pituitary- thyroid axis, causing central hypothyroidism. In the present study, we evaluated pituitary function in 11 male psoriatic patients at baseline and after 1 and 3 months of treatment with acitretin (all-trans retinoic acid, 35 mg/day). Serum LH, FSH, testosterone, cortisol, GH and IGF-I levels were not affected by the treatment. By contrast, we observed a significant decrease in TSH levels (from 0.92±0.3 to 0.80±0.3 mU/l, p<0.05) at 1 month, that reverted to baseline after 3 months. No change in free T4 (FT4) levels occurred, while free T3 (FT3) levels were reduced at 1 and 3 months (from 6.7±0.5 to 6.2±0.3 and 6.1±0.6 pmol/l; p<0.05, respectively). Moreover, acitretin treatment induced a significant reduction of PRL levels after 3 months (from 182±70 to 150±56 mU/l, p<0.05). During treatment, no change in TSH and PRL response either to TRH or dopamine infusion was observed. In conclusion, we demonstrated that treatment with low dose of acitretin induced a series of hormonal modifications that, in addition to a mild and transient reduction of TSH levels, included a persistent reduction of FT3, probably due to changes in thyroid hormone metabolism, and a decrease in PRL levels.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.